Suppr超能文献

与结缔组织疾病相关的肺动脉高压的运动训练。

Exercise training in pulmonary arterial hypertension associated with connective tissue diseases.

机构信息

Centre for Pulmonary Hypertension at Thoraxclinic Heidelberg, Thoraxclinic at the University Hospital Heidelberg, Amalienstrasse 5, Heidelberg, 69126, Germany.

出版信息

Arthritis Res Ther. 2012 Jun 18;14(3):R148. doi: 10.1186/ar3883.

Abstract

INTRODUCTION

The objective of this prospective study was to assess short- and long-term efficacy of exercise training (ET) as add-on to medical therapy in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-APAH).

METHODS

Patients with invasively confirmed CTD-APAH received ET in-hospital for 3 weeks and continued at home for 12 weeks. Efficacy parameters have been evaluated at baseline and after 15 weeks by blinded-observers. Survival rate has been evaluated in a follow-up period of 2.9 ± 1.9 years.

RESULTS

Twenty-one consecutive patients were included and assessed at baseline, and after 3 weeks, 14 after 15 weeks. Patients significantly improved the mean distance walked in 6 minutes compared to baseline by 67 ± 52 meters after 3 weeks (p < 0.001) and by 71 ± 35 meters after 15 weeks (p = 0.003), scores of quality of life (p < 0.05), heart rate at rest, peak oxygen consumption, oxygen saturation and maximal workload. Systolic pulmonary artery pressure and diastolic systemic blood pressure improved significantly after 3 weeks of ET. The 1- and 2-year overall-survival rates were 100%, the 3-year survival 73%. In one patient lung transplantation was performed 6 months after ET.

CONCLUSION

ET as add-on to medical therapy is highly effective in patients with CTD-APAH to improve work capacity, quality of life and further prognostic relevant parameters and possibly improves the 1-, 2- and 3-year survival rate. Further randomized controlled studies are needed to confirm these results.

TRIAL REGISTRATION

ClinicalTrials.gov: NCT00491309.

摘要

简介

本前瞻性研究旨在评估运动训练(ET)作为结缔组织病相关肺动脉高压(CTD-APAH)患者药物治疗的附加手段的短期和长期疗效。

方法

接受有创性确诊的 CTD-APAH 患者在医院接受 3 周的 ET,然后在家中继续接受 12 周的 ET。疗效参数由盲法观察者在基线和 15 周时进行评估。在 2.9±1.9 年的随访期间评估生存率。

结果

连续纳入 21 例患者,在基线时、3 周后和 15 周后进行评估。与基线相比,患者在 3 周后 6 分钟内行走的平均距离增加了 67±52 米(p<0.001),在 15 周后增加了 71±35 米(p=0.003),生活质量评分(p<0.05)、静息心率、峰值摄氧量、氧饱和度和最大工作量也有所改善。ET 治疗 3 周后,收缩期肺动脉压和舒张期全身血压显著改善。1 年和 2 年的总生存率为 100%,3 年生存率为 73%。1 例患者在 ET 后 6 个月进行了肺移植。

结论

ET 作为药物治疗的附加手段,可有效改善 CTD-APAH 患者的工作能力、生活质量和进一步预后相关参数,并可能提高 1 年、2 年和 3 年的生存率。需要进一步的随机对照研究来证实这些结果。

试验注册

ClinicalTrials.gov:NCT00491309。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a34/3446533/11bdab5931b2/ar3883-1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验